Cancer immunotherapy .net
Information on human tumours 2
cancerimmunotherapy@yahoo.com
Tumour type
Bladder cancer
Data in short:

Intravesical IL-2 dimishes recurrences of recurrent superficial bladder cancer.

Clinical phase III study is planned
1995
1998
2001
tumour type
Interleukin-2 (IL-2)
Mechanism of IL-2 therapy of cancer

Cancers sensitive to IL-2
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2

Experts
I want to co-operate (doctors)
Frequently Asked Questions (FAQs)
Information for doctors
Information for patients
I want to support this research or  more information on the EPTI fund supporting this research
Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands
1